DK0866967T4 - Anvendelse af kernemagnetisk resonans til identifikation af ligander til mål-biomolekyler - Google Patents

Anvendelse af kernemagnetisk resonans til identifikation af ligander til mål-biomolekyler

Info

Publication number
DK0866967T4
DK0866967T4 DK96940448T DK96940448T DK0866967T4 DK 0866967 T4 DK0866967 T4 DK 0866967T4 DK 96940448 T DK96940448 T DK 96940448T DK 96940448 T DK96940448 T DK 96940448T DK 0866967 T4 DK0866967 T4 DK 0866967T4
Authority
DK
Denmark
Prior art keywords
ligand
target molecule
ligands
identification
magnetic resonance
Prior art date
Application number
DK96940448T
Other languages
English (en)
Other versions
DK0866967T3 (da
Inventor
Stephen W Fesik
Philip J Hajduk
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24218250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0866967(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of DK0866967T3 publication Critical patent/DK0866967T3/da
Application granted granted Critical
Publication of DK0866967T4 publication Critical patent/DK0866967T4/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Compounds Of Iron (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK96940448T 1995-11-14 1996-11-13 Anvendelse af kernemagnetisk resonans til identifikation af ligander til mål-biomolekyler DK0866967T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/555,691 US5698401A (en) 1995-11-14 1995-11-14 Use of nuclear magnetic resonance to identify ligands to target biomolecules
PCT/US1996/018270 WO1997018471A1 (en) 1995-11-14 1996-11-13 Use of nuclear magnetic resonance to identify ligands to target biomolecules

Publications (2)

Publication Number Publication Date
DK0866967T3 DK0866967T3 (da) 2000-06-26
DK0866967T4 true DK0866967T4 (da) 2007-12-10

Family

ID=24218250

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96940448T DK0866967T4 (da) 1995-11-14 1996-11-13 Anvendelse af kernemagnetisk resonans til identifikation af ligander til mål-biomolekyler

Country Status (13)

Country Link
US (2) US5698401A (da)
EP (2) EP0866967B2 (da)
JP (1) JP3032301B2 (da)
AT (2) ATE189063T1 (da)
AU (1) AU701810B2 (da)
CA (1) CA2237343C (da)
DE (2) DE69606324T3 (da)
DK (1) DK0866967T4 (da)
ES (1) ES2143793T5 (da)
GR (1) GR3032361T3 (da)
IL (2) IL155988A (da)
PT (1) PT866967E (da)
WO (1) WO1997018471A1 (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010004528A1 (en) * 1995-11-14 2001-06-21 Stephen W. Fesik Use of 13c nuclear magnetic resonance to detect binding to target molecules
US5989827A (en) * 1995-11-14 1999-11-23 Abbott Laboratories Use of nuclear magnetic resonance to design ligands to target biomolecules
US6426058B1 (en) * 1996-03-29 2002-07-30 The Regents Of The University Of California Enhancement of NMR and MRI in the presence of hyperpolarized noble gases
DE19649359C1 (de) * 1996-11-28 1998-02-12 Thomas Prof Dr Peters Verfahren zum Nachweis biologisch aktiver Substanzen in Substanzbibliotheken
AU772620B2 (en) * 1997-04-18 2004-05-06 Abbvie Inc. Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
US6043024A (en) * 1997-04-18 2000-03-28 Abbott Laboratories Use of one-dimensional nuclear magnetic resonance to identify ligands to target biomolecules
JP2002505004A (ja) * 1997-06-13 2002-02-12 バーテックス ファマシューティカルズ インコーポレイテッド 薬剤核を同定する方法
US20030143757A1 (en) * 1997-06-13 2003-07-31 Jonathan Moore Methods for identifying drug cores
US6111066A (en) 1997-09-02 2000-08-29 Martek Biosciences Corporation Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US20020131972A1 (en) * 1998-05-21 2002-09-19 Daniel Sem Multi-partite ligands and methods of identifying and using same
WO1999063929A2 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
JP2002534687A (ja) * 1998-12-30 2002-10-15 アメルシャム・パブリック・リミテッド・カンパニー 過分極を使用したｎｍｒ分光学アッセイ
US6897337B2 (en) * 1999-04-09 2005-05-24 Abbott Laboratories Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
TWI283659B (en) * 1999-04-09 2007-07-11 Abbott Lab Site-specific isotopically-labeled proteins, amino acids, and biochemical precursors therefor
US6333149B1 (en) * 1999-06-04 2001-12-25 Triad Biotechnology, Inc. NMR-solve method for rapid identification of bi-ligand drug candidates
US6171804B1 (en) 1999-07-12 2001-01-09 The Rockefeller University Method of determining interdomain orientation and changes of interdomain orientation on ligation
WO2001006260A1 (en) * 1999-07-19 2001-01-25 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
US7105310B1 (en) * 2000-07-19 2006-09-12 California Institute Of Technology Detection of biomolecules by sensitizer-linked substrates
AU6937100A (en) * 1999-08-23 2001-03-19 Polaris Pharmaceuticals, Inc. Inhibitors of binding between proteins and macromolecular ligands
CA2400094A1 (en) * 1999-09-29 2001-04-05 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
JP2003510608A (ja) * 1999-09-29 2003-03-18 スミスクライン・ビーチャム・コーポレイション 標的生体分子と相互作用する化合物を同定するための一次元および多次元核磁気共鳴の使用法
US6677160B1 (en) 1999-09-29 2004-01-13 Pharmacia & Upjohn Company Methods for creating a compound library and identifying lead chemical templates and ligands for target molecules
US6764858B2 (en) 1999-09-29 2004-07-20 Pharmacia & Upjohn Company Methods for creating a compound library
GB9925677D0 (en) * 1999-10-29 1999-12-29 Pharmacia & Upjohn Spa Use of double-quantum 1H-NMR spectroscopy for the identification of ligands interacting with target biomolecules
JP2003524167A (ja) * 2000-02-25 2003-08-12 ワイス Ｍｓ／ｎｍｒを用いた構造に基づく薬物設計の方法
WO2001079852A2 (en) * 2000-04-17 2001-10-25 Pharmacia & Upjohn Company Nmr-methods for indentifying sites in papillomavirus e2 protein
GB0013115D0 (en) * 2000-05-31 2000-07-19 Imp College Innovations Ltd Biological materials and methods for use in the prevention or treatment of infections
US7146277B2 (en) * 2000-06-13 2006-12-05 James H. Prestegard NMR assisted design of high affinity ligands for structurally uncharacterized proteins
US6652833B2 (en) 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
US7061237B2 (en) * 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
US20030165431A1 (en) * 2000-07-13 2003-09-04 The Regents Of The University Of California Method for detecting macromolecular conformational change and binding information
EP2280272A1 (en) 2000-09-27 2011-02-02 Universiteit Leiden Method for applying NMR for ligand discovery or as a drug screening tool
SE0003811D0 (sv) * 2000-10-20 2000-10-20 Pharmacia Ab Screening methods
CA2432924A1 (en) * 2000-12-21 2002-06-27 Triad Therapeutics, Inc. Sea-trosy and related methods
MXPA03005777A (es) * 2000-12-22 2005-02-14 Johnson & Johnson Derivados de triazol diaminas sustituidos como inhibidores de cinasa.
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
US7645569B2 (en) * 2001-01-26 2010-01-12 Board Of Regents, The University Of Texas System NMR detection of foreign PAS domain ligands
US20020172967A1 (en) * 2001-02-13 2002-11-21 Gadek Thomas R. Identification of non-covalent complexes by mass spectrometry
DE10119455B4 (de) * 2001-04-20 2010-12-16 Siemens Ag Verfahren zum Auswerten von Daten, die mittels der Magnetresonanztechnik erzeugt werden und spektroskopische Information beinhalten
CA2448567C (en) 2001-05-25 2014-05-20 Duke University Modulators of nucleic acid ligands
WO2002097450A2 (en) * 2001-05-30 2002-12-05 Triad Therapeutics, Inc. Nuclear magnetic resonance-docking of compounds
US20030129672A1 (en) * 2001-08-29 2003-07-10 Dyer Richard Dennis Method for identifying metalloenzyme inhibitors
US7653490B2 (en) * 2001-09-10 2010-01-26 Triad Liquidating Company LLC Nuclear magnetic resonance assembly of chemical entities
DE10144661C2 (de) * 2001-09-11 2003-08-14 Forschungsverbund Berlin Ev Vorrichtung und Verfahren zur Zuordnung der NMR-Signale von Polypeptiden
US7179450B2 (en) * 2001-09-20 2007-02-20 Medi-Physics, Inc. Methods for in vivo evaluation of pulmonary physiology and/or function using NMR signals of polarized Xe
US7037660B2 (en) * 2001-11-06 2006-05-02 Message Pharmaceuticals Methods for detecting and quantifying binding and inhibition of binding of species to nucleic acids
DE10160177A1 (de) * 2001-12-07 2003-06-26 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden die an ein drug target binden mittels 1H,1H-Kernresonanzspektroskopie
US20040171062A1 (en) * 2002-02-28 2004-09-02 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20030180797A1 (en) * 2002-03-20 2003-09-25 Lin Yu Identification of ligands for a receptor family and related methods
AU2003253589A1 (en) * 2002-03-26 2003-11-10 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
DE10221158A1 (de) * 2002-05-13 2004-02-19 Novaspin Biotech Gmbh Verfahren zur Auffindung von Liganden, die an ein drug target binden, mittels heteronuklearer Kernresonanzspektroskopie
AU2003245433A1 (en) * 2002-06-10 2003-12-22 Prospect Pharma Method for obtaining dynamic and structural data pertaining to proteins and protein/ligand complexes
EP1558751A4 (en) * 2002-09-16 2007-08-22 Plexxikon Inc CRYSTALLINE STRUCTURE OF PROTEIN KINASE PIM-1
WO2006078228A1 (en) * 2002-09-16 2006-07-27 Plexxikon, Inc. Methods for the design of molecular scaffolds and ligands
US20040132102A1 (en) * 2002-10-29 2004-07-08 Maurizio Pellecchia Use of selective labeling to detect and characterize molecular interactions by nuclear magnetic resonance spectroscopy
NO20025738D0 (no) * 2002-11-29 2002-11-29 Amersham Health As Metode
US20050170431A1 (en) * 2003-02-28 2005-08-04 Plexxikon, Inc. PYK2 crystal structure and uses
US7964534B2 (en) * 2003-03-13 2011-06-21 Triad Liquidating Company, Llc Nuclear magnetic resonance assembly of chemical entities using advanced antenna probes
WO2004092727A2 (en) * 2003-04-11 2004-10-28 Structural Genomix, Inc. Compound libraries and methods for drug discovery
EP1617221A4 (en) * 2003-04-23 2006-08-02 Olympus Corp METHOD FOR SCREENING A SUBSTANCE CAPABLE OF BINDING TO A RECEIVER
JP2004331832A (ja) * 2003-05-08 2004-11-25 Ricoh Co Ltd Ｄｎａインク組成物とそれを用いた識別画像印刷体、及びインクジェット記録装置
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7255985B2 (en) * 2003-07-10 2007-08-14 Pfizer Italia S.R.L. Fluorine NMR spectroscopy for biochemical screening
US20050164300A1 (en) * 2003-09-15 2005-07-28 Plexxikon, Inc. Molecular scaffolds for kinase ligand development
WO2005037853A2 (en) * 2003-10-07 2005-04-28 Prospect Pharma Side chain deuterated amino acids and methods of use
JP4192078B2 (ja) * 2003-11-26 2008-12-03 株式会社日立製作所 核磁気共鳴方法
JP4546400B2 (ja) * 2003-11-28 2010-09-15 株式会社日立製作所 核磁気共鳴法を用いた、標的タンパク質のアゴニストおよびアンタゴニストの同定方法、およびこの方法に用いるプログラム
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
US7771938B2 (en) 2004-09-20 2010-08-10 Wisconsin Alumni Research Foundation Nonlinear spectroscopic methods for identifying and characterizing molecular interactions
WO2006082963A1 (ja) * 2005-02-07 2006-08-10 Mitsubishi Chemical Corporation 標的分子とリガンドあるいはリガンド候補化合物との結合検出方法
EP2013624B1 (en) 2006-03-14 2011-08-03 Universität Basel Method for the identification of new leads for drug candidates
US8933209B2 (en) 2006-04-26 2015-01-13 Abbvie Inc. Dep2 and its uses in major depressive disorder and other related disorders
US7760342B2 (en) 2007-12-21 2010-07-20 Wisconsin Alumni Research Foundation Multidimensional spectrometer
US20140024123A1 (en) * 2011-02-07 2014-01-23 National University Corporation Kobe University Aqueous Solution Containing Partial Ras Polypeptide and Method for Screening Inhibitor of Ras Function
KR101855242B1 (ko) 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
WO2017025802A1 (en) 2015-08-11 2017-02-16 Arch Biopartners, Inc. Dpep-1 binding compositions and methods of use
ES2965087T3 (es) 2016-09-02 2024-04-10 Soares Christopher J Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE904705A1 (en) * 1989-12-29 1991-07-17 Univ Technologies Int Methods for modelling tertiary structures of biologically¹active ligands including agonists and antagonists thereto¹and novel synthetic antagonists based on angiotensin
US5164297A (en) * 1990-05-03 1992-11-17 Advanced Magnetics Inc. Solvent mediated relaxation assay system
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5726014A (en) * 1991-06-27 1998-03-10 Genelabs Technologies, Inc. Screening assay for the detection of DNA-binding molecules
DK0593618T3 (da) * 1991-06-27 1998-11-23 Genelabs Tech Inc Screeningsassay til påvisning af DNA-bindende molekyler

Also Published As

Publication number Publication date
AU7732896A (en) 1997-06-05
JPH11513498A (ja) 1999-11-16
DE69606324D1 (de) 2000-02-24
DE69606324T3 (de) 2008-02-07
ATE189063T1 (de) 2000-02-15
GR3032361T3 (en) 2000-04-27
WO1997018471A1 (en) 1997-05-22
ES2143793T3 (es) 2000-05-16
DE69631842D1 (de) 2004-04-15
JP3032301B2 (ja) 2000-04-17
EP0981049B1 (en) 2004-03-10
EP0981049A1 (en) 2000-02-23
AU701810B2 (en) 1999-02-04
PT866967E (pt) 2000-04-28
ES2143793T5 (es) 2008-03-01
DE69606324T2 (de) 2000-07-06
EP0866967A1 (en) 1998-09-30
US5804390A (en) 1998-09-08
EP0866967B2 (en) 2007-08-08
IL123923A (en) 2005-07-25
EP0866967B1 (en) 2000-01-19
US5698401A (en) 1997-12-16
ATE261581T1 (de) 2004-03-15
CA2237343C (en) 2009-01-20
IL155988A (en) 2005-07-25
DK0866967T3 (da) 2000-06-26
CA2237343A1 (en) 1997-05-22
IL155988A0 (en) 2003-12-23
MX9803810A (es) 1998-09-30

Similar Documents

Publication Publication Date Title
DK0866967T3 (da) Anvendelse af kernemagnetisk resonans til identifikation af ligander til mål-biomolekyler
CA2653517A1 (en) Process of designing a drug
DK0870197T4 (da) Anvendelse af nuclear magnetisk resonans til design af ligander rettet mod biomolekyler
BR9808079A (pt) Uso de ressonância nuclear magnética unidimensional para identificar ligantes para biomoléculas alvos
WO1990010709A3 (en) Monoclonal antibodies for metallic cations on small molecules
FR2649526B1 (fr) Procede de fabrication de tetes magnetiques planaires par alveolage d'une plaquette non magnetique, et tetes magnetiques obtenues par un tel procede
ATE197156T1 (de) Verfahren zum nachweis von verbindungen einer konbinatorischen bibliothek.
DK0839152T3 (da) Kombinatoriske biblioteker af mærkede, biokemiske forbindelser og fremgangsmåde til fremstilling af disse
FR2710253B1 (fr) Système magnétique pour tomographie par résonance magnétique nucléaire.
ATE112059T1 (de) Verfahren zur bestimmung eines analyten.
FR2645954B1 (fr) Procede de determination d'une position utilisant des satellites
DE3852906D1 (de) Dipyridoxyl-Phosphat als magnetisches Kernresonanz-Bildgebungsmittel.
NO980292D0 (no) Fremgangsmåte for bestemmelse av vandretidsfelter for seismiske data, ved hjelp av parallelle prosessorer
DE69628194D1 (de) Verfahren zum nachweis von verbindungen die bestimmte zielmoleküle binden
DE69025351D1 (de) Durch Ätzen hergestellte Gradientenspule in Z-Achsenrichtung, für ein magnetisches Kernresonanz-System
Chait et al. Clinical analysis: a perspective on chromatographic and immunoassay technology
DE69717991D1 (de) Ein monoklonaler antikörper, welcher ein apoptotisches antigen nachweist
DE69100611D1 (de) Kompakte Sonde für die magnetische Kernresonanz.
DE59107957D1 (de) Verfahren für die zweidimensionale Kernresonanzspektroskopie
WO2003054532A3 (de) Verfahren zur auffindung von liganden die an ein drug target binden mittels 1h,1h-kernresonanzspektroskopie
CA2237336A1 (en) Use of nuclear magnetic resonance to design ligands to target biomolecules
FR2693813B1 (fr) Procédé de réalisation d'une image de référence synthétisée à partir de données contenues dans une base de données CAO.
ATE344437T1 (de) Verfahren zur filterung von messdaten eines magnetfeldsensors
GRIMES Metallacarborane-based precursors for electroactive materials(Final Report, 1 Jun. 1992- 31 May 1995)
NO180283C (no) Jernholdig preparat for NMR-avbildning